Quality decisions · CAPA effectiveness
Can a CAPA Be Closed if Effectiveness Evidence Is Incomplete?
Not on completed actions alone. Closure requires a reviewable basis for concluding that the action addressed the stated failure mode, that the effectiveness evidence is adequate for the risk and recurrence profile, and that any residual uncertainty has been assessed and authorized.
Direct answer: a CAPA should not be closed merely because assigned actions are complete. The closure decision should show why the available effectiveness evidence is sufficient for the failure mode and risk involved, what uncertainty remains, and who is authorized to accept that residual risk. FDA's quality systems guidance and ICH Q10 discuss monitoring corrective actions and assessing their effectiveness.
The question before closure
The useful question is: What evidence supports the conclusion that the actions addressed the original condition and reduced the risk of recurrence?
A revised procedure, completed training assignment, system configuration, or signed task may demonstrate implementation. None necessarily demonstrates that the underlying cause or control gap was addressed.
What the closure record should show
The original condition
Identify what happened, the affected scope, the quality or compliance risk, and the cause or control gap the CAPA was intended to address. A later reviewer should be able to connect the original condition to the work performed.
The action-to-cause connection
Explain how each action addresses the identified cause. Training can be appropriate when an investigation supports a knowledge or execution gap. If the issue was a weak procedure, missing review, or system design flaw, the record should show how the relevant control changed.
The effectiveness method
Define how effectiveness will be checked before deciding to close. Depending on risk, examine post-implementation records, recurrence trends, routine operation of a new control, related deviations, complaints, audit observations, or batch-record findings. The population and observation period should provide a meaningful opportunity for the failure mode to recur.
The evidence and judgment
State what was reviewed, over what period, what was found, and why the findings supported the decision. Weigh adverse or ambiguous signals. “CAPA was effective. Closed.” preserves almost none of this reasoning.
The closure authority
Identify who evaluated the effectiveness evidence, who authorized closure, and any residual risk, limitation, monitoring owner, or condition for reopening. A signature establishes approval; the rationale explains the judgment behind it.
Where closure reasoning becomes weak
Completion treated as effectiveness
A finished action plan may still lack evidence that the changed control works.
Training treated as proof
Training records show training occurred; they do not independently establish routine performance or control of recurrence.
No meaningful observation period
“No recurrence” is hard to interpret without a defined population, timeframe, and realistic opportunity for the event to happen again.
Evidence disconnected from cause
A large package can still be weak if it does not test the control gap identified by the investigation.
Rationale absent
A date and approval record an administrative event. The effectiveness rationale records the Quality decision.
Closure review questions
- Is the original condition clear enough to reconstruct?
- Does each action address the identified cause, control gap, or risk?
- Was an effectiveness method defined before closure?
- Did the population and timeframe give the failure mode a meaningful chance to recur?
- Does the evidence test the risk the CAPA was meant to control?
- What supporting, adverse, or ambiguous findings were reviewed?
- Are residual uncertainty and continued monitoring visible and owned?
- Who made and authorized the closure decision, and why?
If the record cannot answer these questions, the CAPA may be administratively complete without an explainable effectiveness decision.
A worked example
A site revises a reconciliation step, retrains analysts, and adds a second-person review after a discrepancy was missed in batch review. The closure decision should connect those actions to the original control gap, examine the checkpoint in routine use, describe the records and period reviewed, and explain who accepted the remaining uncertainty.
| Element | Example record |
|---|---|
| Decision | CAPA-24-017 closure authorization. |
| Original condition | Reconciliation discrepancy missed during batch review; potential release-decision exposure. |
| Cause and control gap | Workflow did not require independent confirmation before final signoff. |
| Corrective actions | Procedure revised; reviewer checkpoint added; analysts and reviewers trained. |
| Effectiveness method | Examine every reconciliation event over eight weeks after implementation; verify second-person checks and review the deviation log for repeat or related failures. |
| Evidence and findings | Twenty-six post-change records, reviewer signoffs, and the deviation log reviewed. The checkpoint was recorded in all 26; no repeat discrepancy of the defined type was found in the observed period. |
| Limit and residual risk | The eight weeks and 26 events show operation of the checkpoint in this example. Whether that is enough to close depends on risk and how often the failure had a chance to recur. An adjacent manual handoff remains under monthly monitoring. |
| Closure rationale and authority | QA manager documents the assessment; site Quality head authorizes closure with the limitation and monitoring owner recorded. |
A weak record would preserve only the training completion, revised procedure, and closure signature. The stronger record preserves why the evidence supported the conclusion at that time.
How a decision record helps
For a consequential CAPA closure, an Inspection Response Record can organize the decision summary, known facts, evidence reviewed, risk and residual uncertainty, alternatives or limitations, authorization rationale, and referenced attachments. That is CW's record structure; it does not replace the CAPA or a company's quality system and is not a format prescribed by FDA.
Source context: FDA Quality Systems Approach to Pharmaceutical CGMP Regulations · ICH Q10 Pharmaceutical Quality System. The questions and sample record above are editorial applications of those principles, not quotations or regulatory requirements.